 Lisa Schilling
Concepts (377)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 13 | 2025 | 1132 | 1.360 |
Why?
| | Periodicals as Topic | 11 | 2008 | 217 | 1.250 |
Why?
| | Decision Support Systems, Clinical | 2 | 2022 | 263 | 1.100 |
Why?
| | Comparative Effectiveness Research | 4 | 2017 | 164 | 0.930 |
Why?
| | Patient-Centered Care | 2 | 2024 | 550 | 0.910 |
Why?
| | Quality Improvement | 6 | 2024 | 1254 | 0.880 |
Why?
| | Data Mining | 2 | 2017 | 118 | 0.850 |
Why?
| | Medical Informatics | 5 | 2024 | 101 | 0.840 |
Why?
| | Needs Assessment | 2 | 2025 | 385 | 0.810 |
Why?
| | Information Storage and Retrieval | 7 | 2021 | 120 | 0.800 |
Why?
| | Decision Support Techniques | 2 | 2025 | 431 | 0.800 |
Why?
| | Publishing | 7 | 2007 | 145 | 0.760 |
Why?
| | Maternal Health Services | 1 | 2024 | 103 | 0.760 |
Why?
| | Ultraviolet Rays | 6 | 2015 | 401 | 0.740 |
Why?
| | Hypertension | 6 | 2025 | 1254 | 0.710 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 194 | 0.690 |
Why?
| | Critical Pathways | 1 | 2022 | 106 | 0.690 |
Why?
| | Dermatology | 8 | 2021 | 122 | 0.650 |
Why?
| | Sunbathing | 2 | 2015 | 16 | 0.590 |
Why?
| | Skin Neoplasms | 7 | 2015 | 857 | 0.580 |
Why?
| | Internet | 10 | 2018 | 690 | 0.580 |
Why?
| | Blood Pressure Determination | 1 | 2018 | 145 | 0.530 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2022 | 454 | 0.480 |
Why?
| | Evidence-Based Medicine | 4 | 2024 | 750 | 0.480 |
Why?
| | Medical Record Linkage | 4 | 2024 | 68 | 0.470 |
Why?
| | Primary Health Care | 8 | 2025 | 1809 | 0.470 |
Why?
| | Safety-net Providers | 2 | 2019 | 124 | 0.460 |
Why?
| | Biomedical Research | 5 | 2021 | 708 | 0.460 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 131 | 0.440 |
Why?
| | Leadership | 2 | 2024 | 399 | 0.430 |
Why?
| | Foot Deformities, Congenital | 1 | 2013 | 1 | 0.420 |
Why?
| | Health Maintenance Organizations | 2 | 2011 | 107 | 0.420 |
Why?
| | Contracture | 1 | 2013 | 21 | 0.420 |
Why?
| | Myotonic Dystrophy | 1 | 2013 | 10 | 0.410 |
Why?
| | Attitude of Health Personnel | 4 | 2016 | 1183 | 0.410 |
Why?
| | Humans | 77 | 2025 | 141754 | 0.410 |
Why?
| | Melanoma | 4 | 2021 | 792 | 0.410 |
Why?
| | Spinal Diseases | 1 | 2013 | 51 | 0.410 |
Why?
| | Benchmarking | 2 | 2011 | 180 | 0.400 |
Why?
| | Quality Indicators, Health Care | 3 | 2010 | 308 | 0.400 |
Why?
| | Surveys and Questionnaires | 12 | 2022 | 5974 | 0.390 |
Why?
| | Algorithms | 5 | 2025 | 1768 | 0.380 |
Why?
| | Peer Review, Research | 3 | 2007 | 43 | 0.380 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2018 | 293 | 0.380 |
Why?
| | Databases, Factual | 6 | 2024 | 1448 | 0.370 |
Why?
| | Drug Monitoring | 1 | 2016 | 399 | 0.370 |
Why?
| | Beauty Culture | 4 | 2005 | 11 | 0.370 |
Why?
| | Bone Diseases, Metabolic | 2 | 2022 | 64 | 0.350 |
Why?
| | United States | 27 | 2024 | 15310 | 0.340 |
Why?
| | Total Quality Management | 1 | 2010 | 61 | 0.330 |
Why?
| | Internal Medicine | 5 | 2006 | 273 | 0.330 |
Why?
| | Databases, Bibliographic | 3 | 2004 | 32 | 0.320 |
Why?
| | Information Management | 2 | 2012 | 17 | 0.320 |
Why?
| | Transgender Persons | 2 | 2023 | 200 | 0.300 |
Why?
| | Fractures, Bone | 1 | 2013 | 406 | 0.290 |
Why?
| | Information Dissemination | 1 | 2010 | 224 | 0.280 |
Why?
| | Models, Statistical | 1 | 2012 | 671 | 0.280 |
Why?
| | Tretinoin | 1 | 2009 | 122 | 0.280 |
Why?
| | Cause of Death | 1 | 2009 | 441 | 0.250 |
Why?
| | Anticholesteremic Agents | 2 | 2005 | 155 | 0.250 |
Why?
| | Internship and Residency | 4 | 2006 | 1240 | 0.250 |
Why?
| | Middle Aged | 24 | 2025 | 34647 | 0.250 |
Why?
| | Access to Information | 1 | 2006 | 49 | 0.250 |
Why?
| | Disclosure | 1 | 2007 | 112 | 0.240 |
Why?
| | Female | 33 | 2025 | 75943 | 0.240 |
Why?
| | Clofibric Acid | 1 | 2005 | 1 | 0.240 |
Why?
| | Adult | 21 | 2024 | 39391 | 0.240 |
Why?
| | Aged | 20 | 2025 | 24746 | 0.240 |
Why?
| | Physician-Patient Relations | 5 | 2002 | 585 | 0.240 |
Why?
| | Adolescent | 20 | 2024 | 22130 | 0.230 |
Why?
| | Office Visits | 2 | 2002 | 95 | 0.230 |
Why?
| | Libraries, Digital | 1 | 2004 | 5 | 0.230 |
Why?
| | Archives | 1 | 2004 | 5 | 0.230 |
Why?
| | Remote Consultation | 1 | 2025 | 59 | 0.220 |
Why?
| | Health Information Interoperability | 1 | 2024 | 3 | 0.220 |
Why?
| | Observational Studies as Topic | 1 | 2025 | 124 | 0.220 |
Why?
| | Spain | 5 | 2021 | 46 | 0.220 |
Why?
| | Biological Products | 2 | 2024 | 239 | 0.220 |
Why?
| | Gemfibrozil | 2 | 2006 | 11 | 0.220 |
Why?
| | Comorbidity | 7 | 2022 | 1664 | 0.220 |
Why?
| | Lovastatin | 2 | 2006 | 38 | 0.210 |
Why?
| | Platelet Transfusion | 1 | 2024 | 78 | 0.210 |
Why?
| | Male | 33 | 2025 | 70179 | 0.200 |
Why?
| | Legislation as Topic | 1 | 2003 | 5 | 0.200 |
Why?
| | Antihypertensive Agents | 2 | 2025 | 508 | 0.200 |
Why?
| | Pharmacists | 1 | 2025 | 263 | 0.190 |
Why?
| | Osteoporotic Fractures | 1 | 2023 | 61 | 0.190 |
Why?
| | Meningocele | 1 | 2022 | 2 | 0.190 |
Why?
| | Hospitalization | 6 | 2022 | 2264 | 0.190 |
Why?
| | Anticarcinogenic Agents | 1 | 2003 | 75 | 0.190 |
Why?
| | Programming Languages | 2 | 2021 | 25 | 0.190 |
Why?
| | Osteochondroma | 1 | 2022 | 10 | 0.190 |
Why?
| | Cohort Studies | 9 | 2025 | 5815 | 0.190 |
Why?
| | Young Adult | 10 | 2023 | 13749 | 0.190 |
Why?
| | Erythrocyte Transfusion | 1 | 2024 | 208 | 0.180 |
Why?
| | Blood-Retinal Barrier | 1 | 2021 | 14 | 0.180 |
Why?
| | Computer Communication Networks | 1 | 2021 | 33 | 0.180 |
Why?
| | Patient Acceptance of Health Care | 3 | 2023 | 881 | 0.170 |
Why?
| | Pregnancy Outcome | 1 | 2024 | 457 | 0.170 |
Why?
| | Drug Repositioning | 1 | 2021 | 39 | 0.170 |
Why?
| | Confidentiality | 1 | 2021 | 74 | 0.170 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 323 | 0.170 |
Why?
| | Osteoporosis | 1 | 2023 | 244 | 0.170 |
Why?
| | Perception | 1 | 2023 | 378 | 0.170 |
Why?
| | Quality of Health Care | 3 | 2024 | 658 | 0.170 |
Why?
| | Microvessels | 1 | 2021 | 86 | 0.160 |
Why?
| | Influenza, Human | 3 | 2021 | 626 | 0.160 |
Why?
| | Blood-Brain Barrier | 1 | 2021 | 145 | 0.160 |
Why?
| | Natural Language Processing | 1 | 2021 | 99 | 0.160 |
Why?
| | Aged, 80 and over | 8 | 2023 | 7923 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2021 | 381 | 0.160 |
Why?
| | Faculty, Medical | 1 | 2003 | 296 | 0.160 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 2169 | 0.150 |
Why?
| | Computational Biology | 1 | 2004 | 664 | 0.150 |
Why?
| | Database Management Systems | 2 | 2012 | 51 | 0.150 |
Why?
| | Pandemics | 4 | 2021 | 1656 | 0.150 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 234 | 0.150 |
Why?
| | Alzheimer Disease | 1 | 2025 | 595 | 0.150 |
Why?
| | Blood Pressure | 1 | 2025 | 1748 | 0.150 |
Why?
| | Retina | 1 | 2021 | 314 | 0.140 |
Why?
| | Patient Care Team | 1 | 2024 | 673 | 0.140 |
Why?
| | Student Health Services | 1 | 2018 | 16 | 0.140 |
Why?
| | Pregnancy Complications | 1 | 2024 | 587 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2021 | 260 | 0.140 |
Why?
| | Language | 1 | 2021 | 309 | 0.140 |
Why?
| | Occupational Health | 1 | 2021 | 208 | 0.140 |
Why?
| | Patient Portals | 1 | 2018 | 45 | 0.140 |
Why?
| | Asthma | 2 | 2022 | 1920 | 0.140 |
Why?
| | Qualitative Research | 1 | 2025 | 1547 | 0.140 |
Why?
| | Health Plan Implementation | 1 | 2019 | 145 | 0.140 |
Why?
| | Communication | 2 | 2020 | 951 | 0.130 |
Why?
| | Republic of Korea | 3 | 2021 | 41 | 0.130 |
Why?
| | Artificial Intelligence | 1 | 2021 | 337 | 0.130 |
Why?
| | Phenotype | 1 | 2025 | 3177 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2009 | 1634 | 0.130 |
Why?
| | Authorship | 2 | 2007 | 54 | 0.130 |
Why?
| | Health Care Surveys | 3 | 2016 | 566 | 0.120 |
Why?
| | Curriculum | 3 | 2024 | 1039 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 374 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 371 | 0.110 |
Why?
| | Education, Medical | 2 | 2011 | 271 | 0.110 |
Why?
| | Advance Care Planning | 1 | 2018 | 223 | 0.110 |
Why?
| | Review Literature as Topic | 2 | 2006 | 72 | 0.110 |
Why?
| | Academic Medical Centers | 4 | 2023 | 531 | 0.110 |
Why?
| | Hyperlipidemias | 1 | 2016 | 125 | 0.110 |
Why?
| | Longevity | 1 | 2016 | 175 | 0.110 |
Why?
| | Palliative Care | 1 | 2022 | 822 | 0.110 |
Why?
| | Retrospective Studies | 5 | 2025 | 16374 | 0.110 |
Why?
| | Transcriptome | 1 | 2021 | 1014 | 0.110 |
Why?
| | Health Education | 1 | 2018 | 364 | 0.110 |
Why?
| | Drosophila melanogaster | 1 | 2016 | 237 | 0.110 |
Why?
| | Trichotillomania | 1 | 2014 | 5 | 0.110 |
Why?
| | Health Personnel | 1 | 2021 | 738 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 2 | 2016 | 1344 | 0.110 |
Why?
| | Prevalence | 4 | 2021 | 2799 | 0.100 |
Why?
| | Patient Satisfaction | 4 | 2002 | 697 | 0.100 |
Why?
| | Affective Symptoms | 1 | 2014 | 54 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2017 | 584 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2025 | 1942 | 0.100 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 444 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1866 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1077 | 0.100 |
Why?
| | France | 2 | 2021 | 39 | 0.090 |
Why?
| | Referral and Consultation | 3 | 2023 | 799 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2193 | 0.090 |
Why?
| | Medication Adherence | 1 | 2016 | 513 | 0.090 |
Why?
| | Gene Expression | 1 | 2016 | 1492 | 0.090 |
Why?
| | Obesity | 2 | 2022 | 3008 | 0.090 |
Why?
| | Medical Records Systems, Computerized | 1 | 2012 | 96 | 0.090 |
Why?
| | Ambulatory Care | 3 | 2006 | 587 | 0.090 |
Why?
| | Thalassemia | 1 | 2011 | 7 | 0.090 |
Why?
| | Pregnancy | 1 | 2024 | 7092 | 0.090 |
Why?
| | Planning Techniques | 1 | 2010 | 17 | 0.080 |
Why?
| | Quality Assurance, Health Care | 2 | 2010 | 333 | 0.080 |
Why?
| | Health Services Research | 2 | 2012 | 406 | 0.080 |
Why?
| | Organizational Objectives | 1 | 2010 | 66 | 0.080 |
Why?
| | Cost Savings | 1 | 2010 | 86 | 0.080 |
Why?
| | Disaster Planning | 1 | 2011 | 97 | 0.080 |
Why?
| | Heart Diseases | 1 | 2013 | 335 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 805 | 0.080 |
Why?
| | Child | 7 | 2021 | 22414 | 0.080 |
Why?
| | Health Records, Personal | 1 | 2010 | 28 | 0.080 |
Why?
| | Child, Preschool | 4 | 2021 | 11512 | 0.080 |
Why?
| | Organizational Innovation | 1 | 2010 | 138 | 0.080 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 139 | 0.080 |
Why?
| | Safety Management | 1 | 2010 | 126 | 0.080 |
Why?
| | Organizational Culture | 1 | 2010 | 162 | 0.080 |
Why?
| | Brain | 1 | 2021 | 2868 | 0.070 |
Why?
| | Administration, Topical | 1 | 2009 | 150 | 0.070 |
Why?
| | Emotions | 1 | 2014 | 579 | 0.070 |
Why?
| | Infant | 3 | 2021 | 9843 | 0.070 |
Why?
| | Codes of Ethics | 1 | 2008 | 18 | 0.070 |
Why?
| | Human Experimentation | 1 | 2008 | 14 | 0.070 |
Why?
| | Colorado | 6 | 2024 | 4629 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2010 | 287 | 0.070 |
Why?
| | Self-Evaluation Programs | 1 | 2007 | 6 | 0.070 |
Why?
| | Age Factors | 3 | 2020 | 3294 | 0.070 |
Why?
| | Scientific Misconduct | 1 | 2007 | 12 | 0.060 |
Why?
| | Lung Diseases | 1 | 2013 | 793 | 0.060 |
Why?
| | Ethics, Research | 1 | 2007 | 34 | 0.060 |
Why?
| | Bibliometrics | 1 | 2007 | 65 | 0.060 |
Why?
| | Public Health | 1 | 2011 | 587 | 0.060 |
Why?
| | Smallpox Vaccine | 1 | 2006 | 24 | 0.060 |
Why?
| | Students, Medical | 2 | 2011 | 369 | 0.060 |
Why?
| | Hypolipidemic Agents | 1 | 2006 | 92 | 0.060 |
Why?
| | Knowledge | 1 | 2006 | 59 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2747 | 0.060 |
Why?
| | Medical Staff, Hospital | 1 | 2006 | 82 | 0.060 |
Why?
| | Family Practice | 1 | 2010 | 464 | 0.060 |
Why?
| | Clinical Clerkship | 1 | 2007 | 104 | 0.060 |
Why?
| | Research Design | 2 | 2014 | 1146 | 0.060 |
Why?
| | Indiana | 1 | 2024 | 34 | 0.060 |
Why?
| | Vaccination | 2 | 2021 | 1472 | 0.060 |
Why?
| | Health Level Seven | 1 | 2024 | 2 | 0.060 |
Why?
| | Vocabulary, Controlled | 1 | 2024 | 47 | 0.050 |
Why?
| | Data Accuracy | 1 | 2024 | 65 | 0.050 |
Why?
| | Editorial Policies | 1 | 2004 | 52 | 0.050 |
Why?
| | Blood Banks | 1 | 2024 | 47 | 0.050 |
Why?
| | Taxes | 1 | 2003 | 15 | 0.050 |
Why?
| | Teaching | 1 | 2006 | 237 | 0.050 |
Why?
| | Medical Staff | 1 | 2002 | 17 | 0.050 |
Why?
| | Managed Care Programs | 2 | 2002 | 140 | 0.050 |
Why?
| | Testosterone Congeners | 1 | 2022 | 9 | 0.050 |
Why?
| | Animals | 5 | 2022 | 37749 | 0.050 |
Why?
| | Risk Factors | 3 | 2021 | 10482 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2018 | 1406 | 0.050 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 266 | 0.050 |
Why?
| | Chemoprevention | 1 | 2003 | 95 | 0.050 |
Why?
| | Documentation | 1 | 2004 | 199 | 0.050 |
Why?
| | Osteocytes | 1 | 2022 | 30 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2003 | 185 | 0.050 |
Why?
| | Gender Identity | 1 | 2023 | 127 | 0.050 |
Why?
| | Fibric Acids | 1 | 2021 | 3 | 0.050 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5697 | 0.050 |
Why?
| | Smoking Prevention | 1 | 2003 | 184 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2022 | 99 | 0.050 |
Why?
| | NFATC Transcription Factors | 1 | 2022 | 94 | 0.040 |
Why?
| | Receptors, Notch | 1 | 2022 | 87 | 0.040 |
Why?
| | Canada | 1 | 2003 | 429 | 0.040 |
Why?
| | Common Data Elements | 1 | 2021 | 14 | 0.040 |
Why?
| | Medical Oncology | 1 | 2004 | 317 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2007 | 871 | 0.040 |
Why?
| | Chondrogenesis | 1 | 2022 | 87 | 0.040 |
Why?
| | Ceftriaxone | 1 | 2021 | 20 | 0.040 |
Why?
| | Osteoblasts | 1 | 2022 | 135 | 0.040 |
Why?
| | Administrative Claims, Healthcare | 1 | 2021 | 26 | 0.040 |
Why?
| | Lopinavir | 1 | 2021 | 31 | 0.040 |
Why?
| | Fluoroquinolones | 1 | 2021 | 43 | 0.040 |
Why?
| | Sepsis | 1 | 2007 | 621 | 0.040 |
Why?
| | Blood Platelets | 1 | 2024 | 437 | 0.040 |
Why?
| | Germany | 1 | 2021 | 132 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2022 | 213 | 0.040 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 57 | 0.040 |
Why?
| | Ritonavir | 1 | 2021 | 75 | 0.040 |
Why?
| | China | 1 | 2021 | 220 | 0.040 |
Why?
| | Ambulatory Care Facilities | 1 | 2002 | 248 | 0.040 |
Why?
| | Abnormalities, Multiple | 1 | 2022 | 197 | 0.040 |
Why?
| | Enoxaparin | 1 | 2021 | 67 | 0.040 |
Why?
| | Azithromycin | 1 | 2021 | 98 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 212 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 322 | 0.040 |
Why?
| | Age Distribution | 1 | 2021 | 397 | 0.040 |
Why?
| | Osteogenesis | 1 | 2022 | 199 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 130 | 0.040 |
Why?
| | Biological Transport | 1 | 2021 | 410 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2021 | 455 | 0.040 |
Why?
| | Drug Combinations | 1 | 2021 | 368 | 0.040 |
Why?
| | Medically Underserved Area | 1 | 2000 | 100 | 0.040 |
Why?
| | Complementary Therapies | 1 | 2000 | 90 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 6289 | 0.040 |
Why?
| | Patient Participation | 1 | 2023 | 432 | 0.040 |
Why?
| | Safety | 1 | 2021 | 356 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 258 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 987 | 0.040 |
Why?
| | Narration | 1 | 2020 | 68 | 0.040 |
Why?
| | Estradiol | 1 | 2022 | 528 | 0.040 |
Why?
| | Software Design | 1 | 2018 | 25 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 405 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 11181 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2023 | 498 | 0.040 |
Why?
| | Erythrocytes | 1 | 2024 | 707 | 0.040 |
Why?
| | Skin | 1 | 2003 | 765 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2019 | 125 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2903 | 0.040 |
Why?
| | Occult Blood | 1 | 2018 | 37 | 0.040 |
Why?
| | Family | 1 | 2002 | 680 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 501 | 0.030 |
Why?
| | Vitamin D | 1 | 2021 | 397 | 0.030 |
Why?
| | Overweight | 1 | 2022 | 588 | 0.030 |
Why?
| | Physicians | 1 | 2006 | 942 | 0.030 |
Why?
| | Fiber Optic Technology | 1 | 1997 | 24 | 0.030 |
Why?
| | Spiro Compounds | 1 | 1996 | 14 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1502 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 512 | 0.030 |
Why?
| | Growth Hormone | 1 | 1996 | 102 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2022 | 816 | 0.030 |
Why?
| | Intracranial Pressure | 1 | 1997 | 60 | 0.030 |
Why?
| | Sexual Behavior, Animal | 1 | 2016 | 58 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2092 | 0.030 |
Why?
| | Testis | 1 | 2016 | 158 | 0.030 |
Why?
| | Cooperative Behavior | 2 | 2011 | 463 | 0.030 |
Why?
| | Colonoscopy | 1 | 2018 | 251 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 158 | 0.030 |
Why?
| | United States Public Health Service | 1 | 2015 | 10 | 0.030 |
Why?
| | Smoking | 1 | 2003 | 1603 | 0.030 |
Why?
| | Prospective Studies | 3 | 2003 | 7777 | 0.030 |
Why?
| | Reproduction | 1 | 2016 | 206 | 0.030 |
Why?
| | Mice | 2 | 2022 | 18109 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 1997 | 285 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 2063 | 0.030 |
Why?
| | Neoplasms, Radiation-Induced | 2 | 2005 | 103 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1996 | 325 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 930 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 2006 | 0.030 |
Why?
| | Down-Regulation | 1 | 2016 | 641 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2016 | 254 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1771 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2021 | 962 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 860 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2018 | 779 | 0.030 |
Why?
| | Time Factors | 2 | 2021 | 6966 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 2007 | 0.030 |
Why?
| | Quality of Life | 2 | 2019 | 3014 | 0.020 |
Why?
| | Clinical Competence | 3 | 2007 | 1205 | 0.020 |
Why?
| | Indoles | 1 | 1996 | 478 | 0.020 |
Why?
| | Data Collection | 2 | 2006 | 662 | 0.020 |
Why?
| | Registries | 1 | 2021 | 2144 | 0.020 |
Why?
| | Rats | 1 | 2021 | 5637 | 0.020 |
Why?
| | Genotype | 1 | 2016 | 1866 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2022 | 5909 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4015 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2800 | 0.020 |
Why?
| | Problem-Based Learning | 1 | 2011 | 99 | 0.020 |
Why?
| | Schools, Medical | 1 | 2011 | 152 | 0.020 |
Why?
| | Health Surveys | 1 | 2011 | 513 | 0.020 |
Why?
| | MEDLINE | 1 | 2007 | 23 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5169 | 0.020 |
Why?
| | Clofibrate | 1 | 2006 | 3 | 0.020 |
Why?
| | Bezafibrate | 1 | 2006 | 10 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1374 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2006 | 66 | 0.020 |
Why?
| | Pravastatin | 1 | 2006 | 46 | 0.020 |
Why?
| | Simvastatin | 1 | 2006 | 63 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1508 | 0.020 |
Why?
| | Bioterrorism | 1 | 2006 | 31 | 0.020 |
Why?
| | Quality Control | 1 | 2006 | 171 | 0.020 |
Why?
| | Electronic Mail | 1 | 2006 | 65 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2008 | 275 | 0.010 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2006 | 82 | 0.010 |
Why?
| | Research Personnel | 1 | 2007 | 184 | 0.010 |
Why?
| | Pyrroles | 1 | 2006 | 210 | 0.010 |
Why?
| | Hypermedia | 1 | 2004 | 1 | 0.010 |
Why?
| | Reproducibility of Results | 2 | 2006 | 3356 | 0.010 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 196 | 0.010 |
Why?
| | Computers | 1 | 2004 | 68 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 1057 | 0.010 |
Why?
| | Educational Measurement | 1 | 2007 | 319 | 0.010 |
Why?
| | Beds | 1 | 2003 | 13 | 0.010 |
Why?
| | Interprofessional Relations | 1 | 2006 | 292 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2938 | 0.010 |
Why?
| | Professional Autonomy | 1 | 2002 | 31 | 0.010 |
Why?
| | Gatekeeping | 1 | 2002 | 3 | 0.010 |
Why?
| | Probability | 1 | 2002 | 309 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2537 | 0.010 |
Why?
| | Pilot Projects | 1 | 2007 | 1826 | 0.010 |
Why?
| | Research | 1 | 2004 | 455 | 0.010 |
Why?
| | Random Allocation | 1 | 2001 | 367 | 0.010 |
Why?
| | Incidence | 1 | 2006 | 2806 | 0.010 |
Why?
| | Outpatients | 1 | 2002 | 421 | 0.010 |
Why?
| | Software | 1 | 2004 | 678 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1997 | 175 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2000 | 1317 | 0.010 |
Why?
| | Administration, Oral | 1 | 1996 | 803 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2064 | 0.010 |
Why?
| | Double-Blind Method | 1 | 1996 | 1989 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1997 | 3597 | 0.000 |
Why?
| | Blood Glucose | 1 | 1996 | 2278 | 0.000 |
Why?
|
|
Schilling's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|